What to Expect With Jakafi®


How will my Healthcare Professional monitor me while I’m taking Jakafi?

Before you start treatment, and periodically during treatment, your Healthcare Professional may perform a blood test called a complete blood count.

Your Healthcare Professional may also perform a blood test of your liver function.

The results of these tests can help your Healthcare Professional:

  • Monitor your blood counts and liver function during treatment
  • Adjust your dose of Jakafi, if necessary (most dosage adjustments will happen in the first couple of months but could happen any time during treatment)

Your Healthcare Professional may monitor your blood cholesterol levels, as you may have changes in these levels during your treatment with Jakafi.

Your Healthcare Professional may also perform regular physical examinations, update your medical history, or ask if you are taking any new medicines.

Do not stop taking Jakafi without speaking with your Healthcare Professional. However, if you start bleeding, stop taking Jakafi and call your Healthcare Professional immediately.


What should I communicate to my Transplant Team?

It is important for you and your caregiver to talk to your Transplant Team about how you are feeling and how your condition is affecting you, even if you’re not sure that how you are feeling is caused by your condition. Talking to your Transplant Team helps you both:

  • Understand how your condition is affecting you
  • Follow how your condition is changing over time
  • Discuss options for managing your condition

Photo shows patient and caregiver.

How long will I need to take Jakafi?

How long you continue to take Jakafi depends on your unique situation and how you and your Healthcare Professional decide to move your treatment forward.

After you’ve been taking Jakafi for 6 months, and if you’ve stopped taking your steroids, your Healthcare Professional may begin to gradually lower your Jakafi dose—assuming any signs or symptoms of acute graft-versus-host disease (GVHD) do not return or get worse during this dose adjustment. If signs or symptoms of acute GVHD do return or get worse during this time, your Healthcare Professional may increase your dose of Jakafi again.

Do not stop taking Jakafi without speaking with your Healthcare Professional. However, if you start bleeding, stop taking Jakafi and call your Healthcare Professional immediately.

Image of a Healthcare Professional sitting at a desk talking on the phone about IncyteCARES – patient support program

Already taking Jakafi? IncyteCARES is a patient support program for people taking Jakafi that offers ongoing education and resources

If you and your Healthcare Professional decide that Jakafi is right for you, the registered nurses of IncyteCARES can help eligible patients understand their insurance coverage and financial assistance options, access possible travel cost assistance, plus provide ongoing education and support resources.

IncyteCARES: Connecting to Access, Reimbursement, Education and Support

Learn More
Expand Collapse

INDICATIONS AND USAGE

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, and headache; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.